Navigation Links
Genmab Reaches Milestone in Ofatumumab Collaboration
Date:10/10/2008

Summary: Genmab has Reached the Sixth Milestone in its Ofatumumab

Collaboration With GSK.

COPENHAGEN, Denmark, October 10 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today it has reached the sixth milestone for ofatumumab (HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately DKK 29 million (approximately USD 5.6 million) was triggered by the first patient receiving treatment in the ofatumumab Phase I study in relapsed/refractory follicular non-Hodgkin's lymphoma and chronic lymphocytic leukemia in Japan.

Ofatumumab is an investigational, new generation, human monoclonal antibody that targets a distinct membrane proximal, small loop epitope ( specific binding site) of the CD20 molecule on the surface of B-cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis under a co- development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for sale in any country.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genmab Reaches Fifth Milestone in Ofatumumab Collaboration
2. Genmab A/S - Changes Board/Management/Auditors
3. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
4. Genmab Announces 2008 First Quarter Results
5. Passing of Genmab A/S Annual General Meeting
6. Genmab A/S - Notice to Convene Annual General Meeting
7. Genmabs 2007 Annual Report
8. Genmab Announces Year End 2007 Financial Results
9. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
10. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
11. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... 2015  Pomerantz LLP announces that a class action ... or the "Company")(NYSE: PBYI ) and certain of ... District Court, Central District of California ... a class consisting of all persons or entities who ... 13, 2015 inclusive (the "Class Period").  This class action ...
(Date:7/2/2015)... Md. , July 2, 2015  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... of Spherix Incorporated v. Verizon Services Corp. et ... District Court for the Eastern District of ... on July 1, 2015 interpreting certain key claims in ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate two common ... emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson ... scans and is believed to be the largest brain imaging study ever, will be ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... to the electronics industrys rallying cry of smaller and ... are likely to come from microchips and data storage ... molecules and polymers. With innovative measurement techniques and new ... the March Meeting of the American Physical Society how ...
... March 12 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced ... 11th Annual Global Healthcare Conference in Miami Beach on ... at the Cowen and,Company 28th Annual Healthcare Conference in ... Time. Both presentations are scheduled to,be webcast live and ...
... genetics,(Nasdaq: DCGN ) today announced its consolidated financial ... A conference call to discuss the,year,s results and operating ... 8:00am EDT/12 noon GMT (details below)., Net loss ... million,compared to $85.5 million for the full year 2006. ...
Cached Biology Technology:Copolymers block out new approaches to microelectronics at NIST 2Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences 2deCODE Genetics Announces Full-year 2007 Financial Results 2deCODE Genetics Announces Full-year 2007 Financial Results 3deCODE Genetics Announces Full-year 2007 Financial Results 4deCODE Genetics Announces Full-year 2007 Financial Results 5deCODE Genetics Announces Full-year 2007 Financial Results 6deCODE Genetics Announces Full-year 2007 Financial Results 7deCODE Genetics Announces Full-year 2007 Financial Results 8deCODE Genetics Announces Full-year 2007 Financial Results 9
(Date:6/17/2015)... Maryland , June 17, 2015 ... mit DNA-Tests verbessert den Analyseprozess und senkt Laborkosten    ... Prime Standard: QIA) hat heute in den ... ® für die forensische Analyse ... zur Erstellung genetischer Fingerabdrücke bieten eine integrierte Lösung für ...
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/15/2015)... 2015 According to a new ... (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern ... by MarketsandMarkets, The Natural Language Processing Market is expected ... 18.4% for the forecast period 2015-2020. ... igures spread   through 155 P ages ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... significantly affect variation in voter turnout, shedding new light ... the political system. The research, conducted by political ... San Diego) and psychologist Laura A. Baker (of University ... the American Political Science Review , a journal ...
... Mexico about 10,000 years ago and is now one of ... It is a member of the grass family, which also ... sorghum, and sugar cane. As early agriculturalists selected ... for transforming a wild grass into a food plant. ...
... Cell is ranked cell biology,s top research journal, ... published by ThomsonReuters. In the report, released this month, ... year, placing Cell higher than competing research journals ... Cell is the flagship journal of Cell Press, an imprint ...
Cached Biology News:Why do people vote? Genetic variation in political participation 2Ancient Mexican maize varieties 2Ancient Mexican maize varieties 3
pETDuet-1 is designed for the coexpression of two target genes....
Mouse Laminin-1 MAb (Clone AL-3)...
IEX-1 S/L (H-20)...
... Gia-1. Strong reactivity ... bovine (74%) and guinea pig ... human (31%). Specificity confirmed ... Gat, rat Goa, rat Gia-1, ...
Biology Products: